News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Research published in PNAS by Hydra Biosciences, Inc. is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma



5/19/2009 10:00:12 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences, Inc., a biotech company developing novel ion channel drugs, today announced that research published by Hydra Biosciences scientists and collaborators at Yale University for the first time identified the ion channel TRPA1 as playing an essential role in allergic asthma and demonstrated that Hydra’s TRPA1 antagonist HC-030031 effectively treated allergic asthma in mice. The paper, titled “A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma,” will appear this week in Proceedings of the National Academy of Sciences (PNAS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES